Scientists do not necessarily like the restrictions and regulations of biotechnology, but they need to accept that lawmakers must reflect the wishes and demands of the majority of the population, who are increasingly aware of the potential risks
Julian Kinderlerer
W e have to buckle up when we drive. We are no longer allowed to take scissors or pocket knives in our hand luggage when we fly. Cars have to fulfil a range of safety requirements to be allowed on the streets. Our food must be free of pathogens or any other harmful residues-fast food shops even label coffee cups to warn consumers that the content is hot. There are many who complain that we now live in a 'nanny state' in which the government increasingly polices nearly every aspect of our lives with laws and regulations. This is a response to the risks and hazards that come with new technologies, products and services, and aims to protect consumers and citizens from harm.
In fact, the perception that it is increasingly important to assess any possible risks before introducing something new on the market has changed significantly during the past 50 years. Whereas previously our approach to new technologies was characterized by a "Why not?" attitude, we are now moving closer to asking "Why? Is it really needed?" Consequently, the view today is that technology requires regulation before it is made available to consumers, rather than permitting the market to decide whether it is acceptable. In the past, new products were introduced to the market and if they caused harm or injury, a claim for compensation could be made through the civil law system. Court action would also deter others from repeating the same harmful actions or offering harmful products. This is not the case anymore. Governments and regulatory authorities increasingly demand a proactive risk assessment rather than relying on courts to regulate a new technology reactively. A current example is the introduction of genetically modified (GM) crops and food on the European market, which has been hampered by strict regulations in order to prevent possible risk to consumers and the environment.
During the past 50 years, laws have made food, drugs and other consumer goods safer while improving the safety of the workplace and the environment. This poses a particular challenge to science, which is the source of new technologies. Whereas the practice of scientific research is heavily regulated-so that laboratories are as safe as possible for those working in them-there are many scientists who believe that it is not science that needs regulation but rather the development and use of science. In other words, it is not nuclear physics itself that is harmful, but rather its use in the development of the nuclear bomb. Science should not be inhibited by over-regulation, much as business should not be bound by red tape and should be allowed freedom to innovate, so the argument goes. It is the translation of possible and anticipated risks into laws and regulations that creates much tension between those who demand greater safety and those who feel that innovation and research are t h r e a tened by too many controls. This b e c a m e apparent in March this year when the UK government finally decided to allow a herbicide-tolerant GM maize to be grown in the UK, but its producer, Bayer CropScience (Monheim, Germany), withdrew the crop, blaming governmental overregulation for leaving the maize "economically non-viable" (Burke, 2004) . I will thus describe, using biotechnology as an example, how scientific research and risk assessment have found their way into the legal and legislative system and how that has had an impact on science. W ords in science have no fixed meanings-they change as knowledge and the understanding of biological systems change. By contrast, laws require very precise definitions, in which every word has as little ambiguity as possible in order to allow courts to make just decisions. To scientists, the results often appear clumsy. The UK's 1990 Environmental Protection Act, for example, defines an organism as "any acellular, unicellular or multicellular entity (in any form), other than humans or human embryos; and, unless the context otherwise requires, the term also includes any article or substance consisting of or including biological matter" (Part VI, 
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Section 106). The definition continues: "…it is immaterial, in determining if something is or is not an organism or biological matter, whether it is the product of natural or artificial processes of reproduction and, in the case of biological matter, whether it has ever been part of a whole organism." Similarly, the Convention on Biological Diversity provides an inclusive definition of biotechnology: "'Biotechnology' means any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use" (Convention on Biological Diversity, 1992). These definitions are intentionally broad, so as to provide a means of inclusion. If science comes up with a new discovery, it can be included in these definitions until it is deliberately excluded-either by governmental decree or additional laws.
Such a precise and inclusive text is found in the Cartagena Protocol on Biosafety, which dictates that "'living organism' means any biological entity capable of transferring or replicating genetic material, including sterile organisms, viruses and viroids" and "'Modern biotechnology' means the application of (a) In vitro nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or (b) Fusion of cells beyond the taxonomic family, that overcome natural physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and selection" (Cartagena Protocol to the Convention on Biological Diversity, 2000).
Risk and harm are similarly defined in legal language. These definitions are important because they provide the platform on which all risk assessment and hazard avoidance measures are based. In order to protect individuals from harm, the risks that they may face must be defined and assessed to allow for their identification and management. The report of the US Presidential/ Congressional Commission on Risk Assessment and Risk Management (1997) defines risk as "the probability that a substance or situation will produce harm under specified conditions. Risk is a combination of two factors: The probability that an adverse event will occur (such as a specific disease or type of injury) and the consequences of the adverse event. Risk encompasses impacts on public health and on the environment, and arises from exposure and hazard. Risk does not exist if exposure to a harmful substance or situation does not or will not occur. Hazard is determined by whether a particular substance or situation has the potential to cause harmful effects." B ased on legally binding definitions of risk and biotechnology, most countries have introduced additional health and safety legislation. For example, "a fundamental principle of the British system is that responsibility for health and safety lies with those who own, manage and work in industrial and commercial undertakings.
[…] They must assess the risks attached to their activity and take appropriate action" (UK Health and Safety Commission, 2002) . Employers who create risk are responsible for the protection of their workers and the public from any consequences. Goods must be designed to be safe and without risks to health (UK Health and Safety Commission, 2002) . In general, it is important that the regulatory system for ensuring the safety of those who use products or processes should minimize risk and be proportionate, targeted, consistent and transparent.
The likelihood of the risk being realized must be taken into account in proportion to the impact on individuals or the environment, should the worst case happen. Even if the risk of a serious illness, such as food poisoning, is lower than that posed by the common cold, the hazard is so much greater that extra precautions must be taken to protect individuals. The balance between risk and cost must also be considered, although it may be very difficult to determine costs if a risk is both indirect and delayed. For instance, the liability system does not easily cope with environmental damage that is not directly linked to a particular product or process. This balance between over-and under-regulation is crucial to ensure public acceptance.
The regulatory system also needs to be targeted in order to focus on the problems identified in a hazard analysis and to ensure that any side effects of the process or of the regulatory system are minimized.
Consistency of the regulatory process is important for both producer and consumer acceptance. Lack of consistency would mean that different producers would be treated differently or that they would not be able to predict overall costs or market acceptance of their product. The way in which the European Union regulates the introduction of GM …there are many scientists who believe that it is not science that needs regulation but rather the development and use of science organisms into the environment has failed to provide certainty to applicants, in that they have been given no indication when Europe will make these decisions. In addition, products that are similar to those approved before 1998 have failed to gain approval. Predictability of the process is also crucial. A producer must be able to identify the requirements necessary to assure safety. Responsibilities must be clearly identified and the decision timeframes for regulating authorities must be clear.
Similarly, transparency is important for producers, workers and consumers alike. Regulations must be clear and understandable to those using the technology and to those whose lives may be affected by its use.
They define who decides, when the decision is made, what information is needed to choose between different risk-management options and which questions need to be answered. Also, individuals and companies should have an opportunity to comment on draft regulations and should be given sufficient time to comply with the regulatory system before it comes into effect. In fact, transparency can prevent later opposition, as people rate risks according to "how well the process (giving rise to the hazard) is understood, how equitably the danger is distributed and how well individuals can control their exposure and whether risk is assumed voluntarily" (Fischoff et al, 1978) .
In general, "Risk management is the process of identifying, evaluating, selecting and implementing actions to reduce risk to human health and to ecosystems. The goal of risk management is scientifically sound, cost-effective, integrated actions that reduce or prevent risks while taking into account social, cultural, ethical, political and legal considerations" (US Presidential/ Congressional Commission on Risk Assessment and Risk Management, 1997). Often it is not only laws and regulations that aim to reduce risk, but also governments that attempt to minimize risk by obtaining voluntary compliance with standards rather than using regulation. No matter whether it is compulsory or voluntary, the decision will always be based "on a careful analysis of the weight of scientific evidence that supports conclusions about a problem's potential risks to human health and the environment" (US Presidential/Congressional Commission on Risk Assessment and Risk Management, 1997) . It is also important that the management options are sensitive to political, social, legal and cultural considerations. I t is in fact these latter points-sensitivity to social and cultural considerations-that have made public acceptance of biotechnology so difficult, despite a lack of scientific evidence of a considerable risk to human health or the environment from most consumer products. What makes the situation even more complicated is that different uses of modern biotechnology elicit varying reactions in most countries. Medical and horticultural/floricultural uses are often found to be acceptable, whereas the genetic modification of crops for food use, or the modification of animals and humans, is less acceptable. "While most Americans say they would be in favour of at least some genetically modified food products, and nearly two-thirds believe that genetically modified foods will benefit many people, more than half (56%) say that the issue of genetic modification causes them great concern" (Hallmann et al, 2002) . The greatest controversies centre on GM foods although standards to assure their safety have been established by the Codex Alimentarius Commission (www.codexalimentarius.net), created by the United Nations Food and Agriculture Organization and the World Health Organization, to ensure that consumers receive products that are of a minimum acceptable quality, are safe and do not present a health hazard.
Nevertheless, the public in many countries has been fearful of the application of biotechnology to a wide range of consumer C onsequently, many countries have passed laws and regulations to provide some sense of certainty and to assure consumers that, where possible, any risks have been minimized. Where the risks may be considered unacceptable, or where public opinion makes it impossible to allow the marketing of a product, the law is used as a controlling measure. The UK, for instance, chose to regulate every aspect of the use of GM organisms from very early on-in fact, more or less immediately after it became clear in the mid-1970s that DNA can be transferred between sexually incompatible organisms. Unusually for safety legislation or regulation, the controls were proactive rather than reactive-at that time, little had been done beyond modifying some microorganisms in a few laboratories. In fact, it was scientists who alerted the government to the possible consequences and implications of the new technology-in 1978, Sydney Brenner wrote: "It cannot be argued that this is simply another, perhaps easier way to do It is the translation of possible and anticipated risks into laws and regulations that creates much tension between those who demand greater safety and those who feel that innovation and research are threatened by too many controls special issue
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what we have been doing for a long time with less direct methods. For the first time, there is now available a method which allows us to cross very large evolutionary barriers and to move genes between organisms which have never had genetic contact" (Wright, 1994) .
In 2001, the US Food and Drug Administration (FDA) reconsidered various risk assessments on new foods developed through modern biotechnology. In a proposal requiring that information on plant-derived bioengineered foods for human or animal consumption be submitted to the FDA, they stated that "All plant breeding techniques have the potential to alter food source crops in ways relevant to the legal status of food derived from such crops. However, rDNA technology greatly facilitates, relative to traditional breeding techniques, both the introduction of specific new substances into foods and the directed modification of the composition of foods. This is in part because the technology expands the range of sources of new substances that can be introduced into plants, relative to those that can be introduced with traditional techniques, due principally to rDNA technology's ability to permit the transfer to a food crop of genetic material from virtually any organism. Similarly, at the present time, information related to the genomes of many organisms is rapidly expanding, with the result that newly identified genes are now available to breeders. [...] Given the efficiencies of rDNA techniques, the advances in these techniques, and the rapidly expanding information related to genomes, [the] FDA expects that these techniques are likely to be used to an increasingly greater extent by plant breeders and that the products of this technology are likely in some cases to present more complex safety and regulatory issues than seen to date" (US FDA, 2001) .
Much of the initial regulatory structures assumed that the risk to human health and safety was the most dangerous-it has only been in the past few years that attention has turned to the broader environment. Some countries have reacted by introducing new laws or guidelines, while others have modified existing laws. In 1986, the US government published the 'Coordinated Framework for the Regulation of Biotechnology', which described the "comprehensive federal regulatory policy for ensuring the safety of biotechnology research and products. […] Existing statutes provide a basic network of agency jurisdiction over both research and products; this network forms the basis of this coordinated framework and helps assure reasonable safeguards for the public" (US Office of Science and Technology Policy, 1986) . The Global Environment Facility-an organization in Washington, DC, USA, that supports programmes in developing countries to protect global biodiversity-is currently funding the development and implementation of biosafety laws in more than 130 countries.
The question then is what triggers these laws and regulations: when does an application of biotechnology need to be controlled and regulated? In Europe it is the use of modern biotechnology as defined in a set of Directives (European Commission, 2003) that triggers the regulatory process. In the USA, the trigger tends to be the use of organisms that are pests-plant pests for example-in the manufacture of the organism if the Department of Agriculture is involved. Canada has chosen to use a concept of novelty to trigger the regulatory process. In addition, governments now have to implement the Cartagena Protocol, which states that the trigger is the use of modern biotechnology. Many analyses suggest that once the process is started, then risk assessment and management processes are very similar. Countries have understood that biosafety primarily means protection of the environment, and that the release of living modified organisms needs be regulated in order to protect the environment: "…the environment is not an abstraction but represents the living space, the quality of life and the very health of human beings, including generations unborn" (International Court of Justice, 1996) .
…law requires very precise definitions, in which every word has as little ambiguity as possible in order to allow courts to make just decisions science & society special issue S70 T he controversy over the use of modern biotechnology has centred primarily on commercial releases into the environment, rather than use in laboratories for research, contained use in industry, or use in the production of pharmaceuticals and veterinary products. Nevertheless, as the biotech industry is now the major user of modern biotechnology and the source of new products, the public are rather sceptical. A 2003 Eurobarometer survey showed that there is considerable discrimination among the public-at least in Europetowards the various uses of modern biotechnology. "Europeans continue to distinguish between different types of applications, particularly medical in contrast to agri-food applications" (Gaskell et al, 2003) . For GM crops and GM foods, support declined and opposition increased from 1996 to 1999, and remained stable from 1999 to 2002. GM food, for example, is considered risky, morally unacceptable and not to be encouraged, yet crops-much to the surprise of the researchers-are considered useful but risky, are morally acceptable and are favoured by a slight majority. A Canadian survey showed that "a total of 47.7% of Canadians consider the presence of GM organisms in foods to be dangerous for human health while 20.7% feel they are not dangerous" (Leger Marketing, 2001 ). In the USA, the "American public's position on the acceptability of genetic modification of food is decidedly […] undecided" (Hallman et al, 2002) . A total of 58% of Americans either strongly approve or somewhat approve of creating hybrid plants using genetic modification, while 37% disapprove.
In addition, many nongovernmental organizations have opposed the use of modern biotechnology, especially for food and agriculture, and have started public campaigns against it. Christian Aid for instance, a British charity that works "wherever the need is greatest", believes that GM crops are irrelevant to ending hunger, because the technology puts too much power over food into too few hands and little help is given to small farmers to grow food in sustainable and organic ways. A report on the promises of genetic engineering in developing countries stated "It is tempting to see biotechnology in agriculture as a clean, neutral science, simply transferring progress from the laboratory to the field, improving the lot of everyone. This is illusory. All technologies are embedded in specific economic and social systems and have different costs and benefits" (Burton, 1999) .
T hese responses to the new technology cannot easily be dismissed through assertions by scientists that there is negligible risk, or that permitting transgenic foods and crops should be based solely on science-based risk assessments. If all the scientific information was made available and a consensus could be achieved among scientists that the impact on the environment is minimal, it would be possible to argue for a totally science-based risk assessment process. However, an Irish consultation paper expressed concerns about potential environmental and human health effects because "there is little experience on the interaction of GM organisms with their surrounding environment" (An Taisce, 1998) . Furthermore, the information being provided to the public is probably inadequate, particularly in relation to the labelling of the use of antibiotic-resistance marker genes and herbicide-tolerant crops, which might increase the use and build-up of herbicides in the environment.
These laws and regulations may not always please scientists and those working in the biotechnology industry; in fact, the UK government's resistance to allowing GM crops in Britain has created much uproar within the British scientific community. Equally, US scientists have criticized the USA PATRIOT Act, which limits access to certain types of research that could potentially be misused for bioweapons. But it is important to remember that science and scientists are not the only section of society and that lawmakers have to reflect the opinion of the majority when they discuss laws to increase safety and minimize risks. Scientists do have an important duty to identify the possible risks and hazards of a new technology and to advise lawmakers on how to address these risks. Although the social, economic, moral and legal issues are not within their expertise, they have as much (or as little) right as anyone else to address these questions.
